一、本次权益变动基本情况 万泽实业股份有限公司（以下简称"公司"或"本公司"）的控股股东 万泽集团有限公司（以下简称"万泽集团"）2022 年面向专业投资者非公开 发行可交换公司债券（第二期）（债券简称：22 泽 EB03、22 泽 EB04）以 本公司股票为标的，于 2023 年 6 月 26 日进入换股期，换股期限为 2023 年 6 月 26 日起至 2025 年 12 月 19 日。具体内容详见公司于 2023 年 6 月 15 日 披露的《关于控股股东可交换公司债券进入换股期的提示性公告》（公告编 号：2023-043）。 证券代码：000534 证券简称：万泽股份 公告编号:2026-003 万泽实业股份有限公司 关于控股股东权益变动暨披露简式权益变动报告书的 提示性公告 公司控股股东万泽集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 本次权益变动不会导致公司控股股东、实际控制人发生变更，不会对 公司治理结构及持续性经营产生重大影响。 万泽集 ...

万泽实业股份有限公司 关于控股股东股权质押情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 万泽实业股份有限公司（以下简称"公司"或"本公司"）于近日接到 控股股东万泽集团有限公司（以下简称"万泽集团"）的通知，获悉万泽集 团于2026年1月19日将其持有的本公司无限售条件流通股6,500,000股质押 给徽商银行股份有限公司深圳分行，为其下属企业贷款提供质押担保。具 体情况如下： 证券代码：000534 证券简称：万泽股份 公告编号：2026－004 1 注：万泽集团－红塔证券－23泽EB02担保及信托财产专户、万泽集团－红塔证券－25泽 EB02担保及信托财产专户、万泽集团－红塔证券－25泽EB03担保及信托财产专户、万泽集团－ 红塔证券－25泽EB04担保及信托财产专户系万泽集团有限公司的一致行动人。 4. 控股股东及其一致行动人股份质押情况 一、股东股份质押的基本情况 | 股东 | 是否为控股 股东或第一 | 本次质押 | 占其所 | 占公司 | 是否 | 是否 为补 | | 质押到期 | | 质押 | | --- | --- | --- | ...

万泽股份公告称，自2025年至2026年，因多期可交换公司债券持有人累计换股2248.24万股等原因，控 股股东万泽集团及其一致行动人持股比例由34.53%降至29.75%。本次权益变动前公司总股本5.04亿股， 截至目前为5.10亿股。万泽集团仍是公司控股股东，本次权益变动不涉及公司控制权变更，也不会对公 司治理及经营产生重大影响。 ...

Core Viewpoint - Wanzhou Co., Ltd. (SZ000534) experienced a limit-up on January 19, 2026, reaching a price of 25.14 yuan, with a 10.02% increase, resulting in a total market capitalization of 12.81 billion yuan and a circulating market capitalization of 12.57 billion yuan, with a total transaction amount of 618 million yuan [1]. Group 1 - The rise in Wanzhou's stock price is attributed to governance optimization, high-temperature alloy business growth, and stock incentive plans [2]. - The company is undergoing a governance structure transformation, revising its articles of association and governance systems, which enhances decision-making efficiency [2]. - A stock incentive plan is set to be implemented in 2025, reserving 277,500 shares for core employees, with a high performance assessment target of 119.7% net profit growth by 2027, boosting market confidence [2]. Group 2 - The addition of independent directors with backgrounds in aerospace engines and materials science strengthens the board's professionalism [2]. - The high-temperature alloy business has shown significant revenue growth, contributing to overall performance improvement, and is a core business for the company [2]. - The aerospace sector's increasing demand for high-temperature alloys has attracted market attention, leading to active performance in related stock sectors [2]. Group 3 - Technical indicators suggest that if the MACD forms a golden cross and the stock price breaks through key resistance levels, it may attract more technical investors [2]. - There was a net inflow of large orders on the day, indicating that main funds contributed to the stock's limit-up [2].

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the AI equipment sector, focusing on semiconductor, gas turbine, PCB equipment, and liquid cooling technologies. [1][3] Company Highlights Guanggang Gas - Expected to double new orders from 150,000 cubic meters to approximately 300,000 cubic meters by 2026, with a market capitalization projected to grow from 26 billion to between 80 billion and 100 billion [1][4] - Profit margin anticipated to rise from 10% in 2025 to 34% in the first half of the current year [4] - Actively expanding into overseas markets and developing new products like supercritical carbon dioxide [4] Gas Turbine Sector - Global gas turbine orders expected to increase from 85 GW in 2025 to over 120 GW in 2026, driven by severe electricity shortages in the U.S. [1][5] - Jie Rui is highlighted as a key player, with a potential market capitalization of over 100 billion due to shortened delivery times and strong channel capabilities [5] Gas Turbine Blade Market - Ying Liu and Wan Ze hold less than 2% of a market worth approximately 170 billion, indicating significant growth potential [6] - Improvement in yield rates from 40% to 50-60% expected, enhancing order capacity and profit margins, which currently exceed 40% [6] Lian De Co. - Projected profits for 2026 could exceed expectations, reaching between 350 million and 360 million, with a potential increase to 500 million by 2027 [9] PCB Equipment - Notable companies include Dazhu Laser, New Qiwei, and Kaige, with Dazhu Laser expected to achieve profits of 2 billion by 2026, corresponding to a market cap of 80 billion [10] Liquid Cooling Technology - Companies like Hongsheng and Ying Wei are recommended, with Ying Wei's products being more reliable and likely to enter the U.S. AI supply chain [11] Optical Communication Equipment - Aotewei is identified as a key player with significant market potential in AOI and gold wire bonding machines, with a potential revenue increase of 2 to 2.5 billion if it captures 10% market share [12] Semiconductor Industry - Huahong Semiconductor is highlighted as a key player with a favorable competitive landscape and future growth potential [13] Additional Insights - The gas turbine sector is seen as the most sustainable segment within AI equipment, with increasing demand due to electricity shortages in the U.S. [5] - The liquid cooling technology is noted for its potential to ensure operational stability in data centers, especially under extreme weather conditions [11] - The PCB equipment sector is characterized by limited investment options, making it a secondary focus compared to gas turbines and liquid cooling [3] This summary encapsulates the key points and insights from the conference call, providing a comprehensive overview of the discussed companies and industry trends.

Core Viewpoint - Wanze Co., Ltd. has shown a positive stock performance with a 2.51% increase in intraday trading, reflecting strong market interest and a solid financial performance in recent periods [1][2]. Group 1: Stock Performance - As of January 15, Wanze's stock price reached 22.44 yuan per share, with a market capitalization of 11.434 billion yuan [1]. - The stock has increased by 2.00% year-to-date, 3.99% over the last five trading days, and 38.26% over the last 60 days [1]. - The trading volume was 30.82 million yuan, with a turnover rate of 0.28% [1]. Group 2: Financial Performance - For the period from January to September 2025, Wanze reported a revenue of 941 million yuan, representing a year-on-year growth of 21.00% [2]. - The net profit attributable to shareholders was 170 million yuan, reflecting a year-on-year increase of 22.45% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased to 26,900, a reduction of 0.83% from the previous period [2]. - The average number of circulating shares per shareholder increased by 0.84% to 18,595 shares [2]. - The company has distributed a total of 645 million yuan in dividends since its A-share listing, with 107 million yuan distributed in the last three years [3].

Group 1 - The article emphasizes the importance of the "2026 Global Health Industry Innovation Conference" to promote high-quality development in the health sector, aligning with national strategies for innovation and health [2][5] - The global health industry is undergoing a transformation driven by disruptive technologies such as artificial intelligence and big data, which are reshaping traditional medical practices and providing new solutions for public health challenges [4] - The conference will gather experts from various fields, including government officials, academicians, and industry representatives, to discuss the future of the health industry and collaborate on innovative solutions [5][6] Group 2 - The conference is scheduled for January 18, 2026, at the Zhongguancun International Innovation Center in Beijing, with various supporting and co-organizing institutions involved [15][16] - A series of parallel forums will take place during the conference, focusing on topics such as medical service innovation, AI in healthcare, and the integration of traditional Chinese medicine with modern technology [19][20] - The main forum will feature distinguished speakers discussing topics like brain-machine interfaces, intelligent medical imaging, and the role of AI in healthcare, highlighting the integration of technology in medical practices [20][21]

Group 1 - The core point of the news is that Wanzhe Co., Ltd. experienced a stock price increase of 6.12%, reaching 22.90 yuan per share, with a total market capitalization of 11.669 billion yuan [1] - Wanzhe Co., Ltd. is based in Shenzhen, Guangdong, and was established on November 4, 1992, with its listing date on January 10, 1994. The company specializes in the research, production, and sales of micro-ecological preparations and high-temperature alloys [1] - The main revenue composition of Wanzhe Co., Ltd. includes: Jindouqi at 48.91%, high-temperature alloy material sales at 26.30%, Dingjunsheng at 23.12%, and other services at 1.62% [1] Group 2 - Longxin National Defense and Military Industry Quantitative Mixed A Fund (002983) is among the top ten circulating shareholders of Wanzhe Co., Ltd., holding 11.7722 million shares, which is 2.35% of the circulating shares [2] - The fund has achieved a year-to-date return of 6.97% and a one-year return of 69.69%, ranking 759 out of 8827 and 763 out of 8084 in its category, respectively [2] - The fund manager, Song Hai'an, has been in position for 7 years and 334 days, with the fund's total asset scale at 6.495 billion yuan and the best return during his tenure being 179.05% [3]

Core Viewpoint - Wanze Group plans to reduce its stake in Wanze Industrial Co., Ltd. by up to 8 million shares, representing 1.6585% of the company's total share capital, to meet its own funding needs [1] Group 1 - Wanze Group will initiate the share reduction starting from January 27, 2026, over a period of three months [1] - The reduction will be executed through centralized bidding or block trading methods [1] - The shares to be reduced are sourced from those previously acquired by Wanze Group through block trading [1] Group 2 - The maximum reduction will not exceed 25% of the total shares held by Wanze Group and its concerted parties [1]

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]